Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
108 hedge funds and large institutions have $30.2M invested in Mersana Therapeutics in 2025 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 22 increasing their positions, 31 reducing their positions, and 48 closing their positions.
140% more call options, than puts
Call options by funds: $12K | Put options by funds: $5K
0.56% less ownership
Funds ownership: 3.38% → 2.82% (-0.56%)
16% less funds holding
Funds holding: 128 → 108 (-20)
29% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 31
42% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 48
80% less capital invested
Capital invested by funds: $149M → $30.2M (-$119M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.39M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.17M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.91M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.85M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$815K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$16.2M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$6.08M |
| 3 |
VA
VR Adviser
New York
|
-$4.13M |
| 4 |
BCM
Boxer Capital Management
San Diego,
California
|
-$3.77M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.6M |
MRSN Hedge Fund Activity: Q1 2025 in Review
108 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q1 2025, worth a combined $30.2M — down 80% from $149M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of MRSN and 28 opened new positions — a net loss of 20 holders — while 31 trimmed existing stakes and 22 added.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $3.39M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $16.2M sold.
- 108 institutional investors held Mersana Therapeutics (MRSN) as of Q1 2025, down from 128 in Q4 2024.
- Funds reported $30.2M of Mersana Therapeutics stock for Q1 2025, down 80% quarter-over-quarter.
- 28 funds opened new Mersana Therapeutics positions in Q1 2025 and 48 closed out, a net change of -20 holders.
- The largest Mersana Therapeutics buyer in Q1 2025 was Schonfeld Strategic Advisors, an estimated $3.39M added.
- The largest Mersana Therapeutics seller in Q1 2025 was EcoR1 Capital, an estimated $16.2M sold.
Based on aggregated 13F filings for Q1 2025.